848819-82-9Relevant academic research and scientific papers
MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES
-
Page/Page column 135; 143; 144, (2021/11/06)
The present disclosure relates to novel compounds for use in therapeutic treatement of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.
Synthesis and bioevaluation of pyrazole-benzimidazolone hybrids as novel human 4-Hydroxyphenylpyruvate dioxygenase inhibitors
Xu, Yu-Ling,Lin, Hong-Yan,Ruan, Xu,Yang, Sheng-Gang,Hao, Ge-Fei,Yang, Wen-Chao,Yang, Guang-Fu
, p. 427 - 438 (2015/03/05)
4-Hydroxyphenylpyruvate dioxygenase (HPPD), an essential enzyme in tyrosine catabolism, is an important target for treating type I tyrosinemia. Inhibition of HPPD can effectively alleviate the symptoms of type I tyrosinemia. However, only one commercial H
Synthesis and potent antimicrobial activity of some novel methyl or ethyl 1H-benzimidazole-5-carboxylates derivatives carrying amide or amidine groups
Oezden, Seckin,Atabey, Dilek,Yildiz, Sulhiye,Goeker, Hakan
, p. 1587 - 1597 (2007/10/03)
A series of benzimidazole-5-carboxylic acid alkyl ester derivatives carrying amide or amidine substituted methyl or phenyl groups at the position C-2 were synthesised and evaluated for antibacterial and antifungal activities against S. aureus, methicillin
